Mesalazine and Lactoferrin as Potential Adjuvant Therapy in Colorectal Cancer: Effects on Cell Viability and Wnt/β-Catenin Pathway

Colorectal cancer (CRC) remains one of the leading causes of cancer-related deaths, meaning it is essential to explore all possible strategies for its prevention and treatment. Unfortunately, risk factors such as an unhealthy lifestyle, lack of exercise, and obesity—which are increasingly prevalent...

Full description

Saved in:
Bibliographic Details
Main Authors: Joanna Słoka, Marcel Madej, Ilona Nowak, Barbara Strzałka-Mrozik
Format: Article
Language:English
Published: MDPI AG 2025-05-01
Series:Current Issues in Molecular Biology
Subjects:
Online Access:https://www.mdpi.com/1467-3045/47/5/327
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850257452573917184
author Joanna Słoka
Marcel Madej
Ilona Nowak
Barbara Strzałka-Mrozik
author_facet Joanna Słoka
Marcel Madej
Ilona Nowak
Barbara Strzałka-Mrozik
author_sort Joanna Słoka
collection DOAJ
description Colorectal cancer (CRC) remains one of the leading causes of cancer-related deaths, meaning it is essential to explore all possible strategies for its prevention and treatment. Unfortunately, risk factors such as an unhealthy lifestyle, lack of exercise, and obesity—which are increasingly prevalent in developed countries—contribute to CRC development. The aim of this study was to evaluate the effect of a mesalazine (MES) and lactoferrin (LACT) combination on the viability of CRC cells and healthy intestinal epithelial cells, as well as to assess the expression profile of target genes within the Wnt/β-catenin pathway. Additionally, this study aimed to preliminarily analyze the mechanism of action underlying the combined effects of these compounds. In this study, we used three CRC cell lines (HCT-116, DLD-1, and HT-29) along with the healthy intestinal epithelial cell line CCD 841 CoN. These cells were treated with MES and LACT separately, as well as in combination. We demonstrated that the combination of MES and LACT reduced the viability of CRC cells more effectively than either compound alone, while slightly increasing the viability of normal intestinal epithelial cells. The synergistic effect of MES and LACT may serve as a foundation for developing new treatment strategies for CRC, utilizing compounds with a high safety profile.
format Article
id doaj-art-99ca443183524ac88ced5ced363148cb
institution OA Journals
issn 1467-3037
1467-3045
language English
publishDate 2025-05-01
publisher MDPI AG
record_format Article
series Current Issues in Molecular Biology
spelling doaj-art-99ca443183524ac88ced5ced363148cb2025-08-20T01:56:25ZengMDPI AGCurrent Issues in Molecular Biology1467-30371467-30452025-05-0147532710.3390/cimb47050327Mesalazine and Lactoferrin as Potential Adjuvant Therapy in Colorectal Cancer: Effects on Cell Viability and Wnt/β-Catenin PathwayJoanna Słoka0Marcel Madej1Ilona Nowak2Barbara Strzałka-Mrozik3Department of Molecular Biology, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, 40-055 Katowice, PolandDepartment of Molecular Biology, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, 40-055 Katowice, PolandDepartment of Molecular Biology, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, 40-055 Katowice, PolandDepartment of Molecular Biology, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, 40-055 Katowice, PolandColorectal cancer (CRC) remains one of the leading causes of cancer-related deaths, meaning it is essential to explore all possible strategies for its prevention and treatment. Unfortunately, risk factors such as an unhealthy lifestyle, lack of exercise, and obesity—which are increasingly prevalent in developed countries—contribute to CRC development. The aim of this study was to evaluate the effect of a mesalazine (MES) and lactoferrin (LACT) combination on the viability of CRC cells and healthy intestinal epithelial cells, as well as to assess the expression profile of target genes within the Wnt/β-catenin pathway. Additionally, this study aimed to preliminarily analyze the mechanism of action underlying the combined effects of these compounds. In this study, we used three CRC cell lines (HCT-116, DLD-1, and HT-29) along with the healthy intestinal epithelial cell line CCD 841 CoN. These cells were treated with MES and LACT separately, as well as in combination. We demonstrated that the combination of MES and LACT reduced the viability of CRC cells more effectively than either compound alone, while slightly increasing the viability of normal intestinal epithelial cells. The synergistic effect of MES and LACT may serve as a foundation for developing new treatment strategies for CRC, utilizing compounds with a high safety profile.https://www.mdpi.com/1467-3045/47/5/327mesalazinelactoferrincolorectal canceriron metabolism
spellingShingle Joanna Słoka
Marcel Madej
Ilona Nowak
Barbara Strzałka-Mrozik
Mesalazine and Lactoferrin as Potential Adjuvant Therapy in Colorectal Cancer: Effects on Cell Viability and Wnt/β-Catenin Pathway
Current Issues in Molecular Biology
mesalazine
lactoferrin
colorectal cancer
iron metabolism
title Mesalazine and Lactoferrin as Potential Adjuvant Therapy in Colorectal Cancer: Effects on Cell Viability and Wnt/β-Catenin Pathway
title_full Mesalazine and Lactoferrin as Potential Adjuvant Therapy in Colorectal Cancer: Effects on Cell Viability and Wnt/β-Catenin Pathway
title_fullStr Mesalazine and Lactoferrin as Potential Adjuvant Therapy in Colorectal Cancer: Effects on Cell Viability and Wnt/β-Catenin Pathway
title_full_unstemmed Mesalazine and Lactoferrin as Potential Adjuvant Therapy in Colorectal Cancer: Effects on Cell Viability and Wnt/β-Catenin Pathway
title_short Mesalazine and Lactoferrin as Potential Adjuvant Therapy in Colorectal Cancer: Effects on Cell Viability and Wnt/β-Catenin Pathway
title_sort mesalazine and lactoferrin as potential adjuvant therapy in colorectal cancer effects on cell viability and wnt β catenin pathway
topic mesalazine
lactoferrin
colorectal cancer
iron metabolism
url https://www.mdpi.com/1467-3045/47/5/327
work_keys_str_mv AT joannasłoka mesalazineandlactoferrinaspotentialadjuvanttherapyincolorectalcancereffectsoncellviabilityandwntbcateninpathway
AT marcelmadej mesalazineandlactoferrinaspotentialadjuvanttherapyincolorectalcancereffectsoncellviabilityandwntbcateninpathway
AT ilonanowak mesalazineandlactoferrinaspotentialadjuvanttherapyincolorectalcancereffectsoncellviabilityandwntbcateninpathway
AT barbarastrzałkamrozik mesalazineandlactoferrinaspotentialadjuvanttherapyincolorectalcancereffectsoncellviabilityandwntbcateninpathway